Trump urging more research into psychedelic ibogaine
perigon
Last updated: April 17, 2026
President Donald Trump is poised to sign an executive order promoting research into the psychedelic ibogaine. This move signals a potential shift in government interest towards exploring the therapeutic benefits of substances previously categorized as illicit. The order is expected to encourage federal agencies to investigate ibogaine's potential applications, particularly in areas like addiction treatment.
- The executive order aims to accelerate scientific understanding of ibogaine's effects.
- It will likely direct federal agencies to increase funding and support for ibogaine research.
- A primary focus of this research is expected to be the treatment of opioid addiction and other substance use disorders.
- The order signifies a potential re-evaluation of federal drug policy regarding certain psychedelics.
- This initiative aligns with growing interest in alternative treatment methods for mental health and addiction.
- The move could pave the way for more clinical trials and studies on ibogaine's efficacy and safety.
- Specific details of the order and the agencies involved are anticipated to be released upon its signing.
- The potential impact on drug policy and the accessibility of ibogaine-assisted therapies remains to be seen.
